Accounting for noncompliance in pharmacoeconomic evaluations.
about
A review of medication adherence in people with epilepsy.Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trialPrevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data.Measuring therapy adherence in Parkinson's disease: a comparison of methodsThe NICE ADHD health technology assessment: a review and critiqueSystematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophreniaCompliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis.High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational studyEconomic impact of poor compliance with pharmaceuticals.Cost offset of lipid-lowering drugs for primary and secondary prevention of cardiovascular disease.Inclusion of compliance and persistence in economic models: past, present and future.The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people: a systematic review.Medication adherence in patients with Parkinson's disease.Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.Economic impact of medication non-adherence by disease groups: a systematic review.Adherence to Treatment in Hypertension.
P2860
Q30244080-E92B071E-1F57-4A6F-AD17-83B188949D27Q30590794-F233A981-F73C-4829-8288-AF064A7C3644Q33290999-31DEFBBA-918B-45F1-BE77-8CECDE75715DQ33529426-7555EFE9-5AF7-440E-9779-C5351E90743DQ36142605-D1AFBE48-DF3F-40E1-8427-B0751BDF0215Q36491460-1BBE4E28-958F-4D11-9359-FE5DE21F59A4Q36755049-1092F29C-965C-4EFE-8358-7292D153400AQ37028983-AA0D10E4-8572-40FF-B385-13403850A81CQ37299151-D74B808F-29FA-4E7A-89B0-4CB0C93DD86FQ37609268-34582818-1D2B-4751-8BB4-5C8ECF18BDFAQ37609394-7EA09201-58B0-40A7-BE8D-8BEE1EF23DCCQ38048913-B128A0D3-1C34-4765-ACF8-E5D68BE9FBE9Q38085227-1F5CFCDB-74AC-48CE-9B8F-AEBF1D2F6CE8Q38287369-7B9331FF-3A8C-4687-A56F-0BA75E29653AQ38692558-ADE57224-BAF8-4F1A-9996-A7F38D7F1F08Q47555825-9AF479E0-6EA2-475E-B2CE-2892B63EC648Q48967636-908DE4F2-B323-4608-9567-4A476F00E9D6
P2860
Accounting for noncompliance in pharmacoeconomic evaluations.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Accounting for noncompliance in pharmacoeconomic evaluations.
@ast
Accounting for noncompliance in pharmacoeconomic evaluations.
@en
Accounting for noncompliance in pharmacoeconomic evaluations.
@nl
type
label
Accounting for noncompliance in pharmacoeconomic evaluations.
@ast
Accounting for noncompliance in pharmacoeconomic evaluations.
@en
Accounting for noncompliance in pharmacoeconomic evaluations.
@nl
prefLabel
Accounting for noncompliance in pharmacoeconomic evaluations.
@ast
Accounting for noncompliance in pharmacoeconomic evaluations.
@en
Accounting for noncompliance in pharmacoeconomic evaluations.
@nl
P2093
P1433
P1476
Accounting for noncompliance in pharmacoeconomic evaluations.
@en
P2093
P304
P356
10.2165/00019053-200119120-00001
P577
2001-01-01T00:00:00Z
P6179
1011487615